Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S26 pseudogene 11 (RPS26P11) is classified as a pseudogene in the human genome and is not believed to encode a functional protein. It is predicted, based on sequence homology, to have possible mRNA binding function and to act as a structural constituent of ribosomes, similar to its parent gene; however, these functions are not experimentally validated and no protein product has been confirmed. As a pseudogene, RPS26P11 does not act as a druggable target, does not interact with any known therapeutic agents, and is not directly associated with any diseases[1][3][4][6][7][8].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S26 pseudogene 11 (RPS26P11).